Clinical Trials Browser

Phase 1/2 × Myeloproliferative Disorders × CPX-351 × Clear all

NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Phase 1/2 Terminated

12 enrolled 15 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis